Number of the records: 1  

Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use

  1. 1.
    0559932 - ÚOCHB 2023 RIV eng P - Patent Document
    Hocek, Michal - Tichý, Michal - Hajdúch, M. - Džubák, P.
    Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use.
    2022. Owner: Ústav organické chemie a biochemie AV ČR, v. v. i. – Univerzita Palackého v Olomouci. Date of the patent acceptance: 10.08.2022. Patent Number: EP3478701
    R&D Projects: GA TA ČR(CZ) TE01020028; GA ČR(CZ) GA16-00178S; GA MZd(CZ) NV15-31984A
    Institutional support: RVO:61388963
    Keywords : nucleosides * fused heterocycles * cytostatics
    OECD category: Medicinal chemistry
    https://worldwide.espacenet.com/patent/search/family/056550662/publication/EP3478701B1?q=EP3478701B1

    Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use The invention provides a new group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, wherein R is defined in the claims. The compounds of this invention show strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.
    Permanent Link: https://hdl.handle.net/11104/0333049

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.